Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
DrugOther names: Vigadexa®
NCT Number: NCT01859702
The purpose of this study was to determine the moxifloxacin aqueous penetration when dosing with a combination drug Vigadexa preoperatively in cataract patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Vigadexa®
Time frame: Day 3 (operative day)
A 0.150 milliliter sample of the aqueous humor was obtained during cataract surgery. The concentration of moxifloxacin was measured by a validated procedure using high performance liquid-spectrometry.
Alcon Research
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07735000
Age Related Cataract, Cataract
Peshawar, KPK, Pakistan
View Trial DetailsNCT07605260
Cataract, Eye Diseases
Islamabad, Punjab Province, Pakistan
View Trial DetailsNCT06428955
Cataract, Eye Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT06111222
Cataract, Eye Diseases
Heidelberg, Germany
View Trial Details